Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Artiva Biotherapeutics Inc fell by 49.01m. Cash Flow from Financing totalled 24.39m or 72.83% of revenues. In addition the company used 47.43m for operations while cash used for investing totalled 25.98m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.09 |
---|---|
Tangible book value per share | 1.09 |
More ▼
Balance sheet in USDView more
Current ratio | 4.59 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0088 |
---|---|
Total debt/total capital | 0.0087 |
More ▼